Organization
Clinica São Germano, São Paulo, Brazil
4 abstracts
Abstract
A phase 3, open-label, randomized study to evaluate the efficacy and safety of single-agent belantamab mafodotin (belamaf) compared to pomalidomide plus low-dose dexamethasone (Pd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): DREAMM‑3.Org: Clinica São Germano, São Paulo, Brazil, General Hospital Evangelismos, Athens, Greece, Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary, Centro Integrado de Hematologia e Oncologia, Hospital Mãe de Deus, Porto Alegre, Brazil, GSK, Upper Providence, PA,
Abstract
DREAMM-7 update: Subgroup analyses from a phase 3 trial of belantamab mafodotin (belamaf) + bortezomib and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM).Org: Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cáncer (IBMCC-USAL, CSIC), Medical University of Lodz, Samodzielny Publiczny Szpital Kliniczny,
Abstract
Patient-reported outcomes (PROs) from the DREAMM-7 randomized phase 3 study comparing belantamab mafodotin, bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma (RRMM).Org: Clinica São Germano, São Paulo, Brazil, Medical University of Lodz, Lodz, Poland, Samodzielny Publiczny Szpital Kliniczny, Lublin, Poland, The First Affiliated Hospital of Soochow University, Suzhou, China, Gorodskaya Klinicheskaya Bol'nitsa Im. Botkina, Moscow, Russian Federation,
Abstract
MajesTEC-9: A randomized phase 3 study of teclistamab versus pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.Org: Centre Hospitalier Universitaire de Nantes, Clinica São Germano, São Paulo, Brazil, Columbia University Medical Center, Sylvester Comprehensive Cancer Center, Miami, FL, Janssen Research & Development,